Ovid call to discuss Phase 2 trial achieving endpoints
Ovid conference call to discuss Phase 2 STARS trial of OV101 achieved its primary endpoint of safety and tolerability will be held on August 6 at 8 am. http://investors.ovidrx.com/phoenix.zhtml?c=254470&p=irol-calendar
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.